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Abstract
Background: Immunotherapy for food allergy requires prolonged treatment proto‐
cols and, in most cases, does not lead to durable modulation of the allergic immune 
response. We have demonstrated an intranasal (IN) nanoemulsion adjuvant that re‐
directs allergen‐specific Th2 responses toward Th1 and Th17 immunity, and protects 
from allergen challenge after only 2‐4 monthly administrations. Here, we investigate 
the ability of this technology to provide long‐term modulation of allergy in a murine 
model of cow's milk allergy.
Methods: Six weeks after sensitization to bovine casein, mice received four, monthly 
IN immunizations with nanoemulsion formulated with casein. Protection from casein 
challenge was assessed at 4 and 16 weeks after the final vaccine administration.
Results: The NE vaccine significantly blunted the physiological responses to aller‐
gen challenge, and this effect persisted for at least 16 weeks. The protection from 
challenge was associated with the suppression of casein‐specific Th2 immunity and 
induced Th1 and Th17 cytokines as well as induction of IL‐10. Of interest, while im‐
munized animals showed significantly decreased Th2 cytokine responses, cow's milk‐
specific IgE remained elevated in the serum at levels associated with reactivity in 
control sensitized animals. Protection was associated with suppressed mast cell acti‐
vation and markedly reduced mast cell infiltration into the small intestine.
Conclusion: The sustained unresponsiveness of at least 16 weeks after vaccination 
suggests that the nanoemulsion vaccine alters the allergic phenotype in a persistent 
manner different from traditional desensitization, and this leads to long‐term sup‐
pressive effects on allergic disease without eliminating serum IgE.
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1  | INTRODUC TION
Food allergies have become common in industrialized nations and 
affect an estimated 5% of adults and 8% of children in the United 
States.1,2 Milk is one of the eight major allergens responsible for the 
majority of serious food allergy reactions in the United States, and 
allergy to cow's milk is the most common food allergy in infants and 
young children.3 While cow's milk allergy is often outgrown, high 
milk‐specific IgE in infants is associated with persistent milk allergy 
as well as increased incidence of atopic dermatitis, asthma, rhino‐
conjunctivitis, and other food allergies.4,5
Strict avoidance of an offending food is the primary clinical 
approach to prevent allergic reactions and anaphylaxis, often cou‐
pled with the use of epinephrine for accidental exposure. Recently, 
however, progress has been made toward the development of im‐
munotherapy for food allergy. This includes oral (OIT), sublingual 
(SLIT), and epicutaneous (EPIT) immunotherapies (reviewed in6,7), 
and single‐allergen OIT for peanut allergy has been submitted to 
the FDA for approval.8‐10 OIT has also been studied for milk allergy 
in numerous clinical trials.11 However, most evidence suggests 
that OIT is not effective to induce tolerance or durable sustained 
unresponsiveness (SU) to food allergens. SU, as defined by the 
ability to pass a double‐blind, placebo‐controlled food challenge 
(DBPCFC) 2‐8 weeks after cessation of the immunotherapy, has 
been reported to occur in 25%‐58% of trial participants,12‐14 and 
this included patients that may have naturally outgrown their al‐
lergy. Thus, while these immunotherapies have demonstrated ef‐
ficacy, this lack of sustained protection suggests that OIT in most 
cases does not fundamentally change the allergen‐specific allergic 
response.
An optimal goal for treating food allergies would be to generate 
immune tolerance in allergic individuals and suppress the underlying 
Th2‐polarized cellular immune responses, including IL‐4 and IL‐13, and 
allergen‐specific IgE antibodies.1,15‐17 Recent work has demonstrated 
that the induction of tolerance in allergies is associated with both the 
suppression of mast cell and basophil reactivity and changes in allergen‐
specific cells, including the upregulation of regulatory markers and in‐
creases in the number and/or function of regulatory T cells (Tregs). Thus, 
the goal of approaches for long‐term SU or tolerance to prevent allergic 
reactions could include both the durable suppression of allergen‐specific 
Th2 immunity and reductions in number and reactivity of effector cells.
Our group has developed an intranasal nanoemulsion (NE) ad‐
juvant that modulates preexisting allergen‐specific Th2 immune 
responses toward a Th1 and Th17 phenotype.18 We previously 
reported that in murine models of peanut allergy, this modulation 
resulted in protection when mice were challenged with peanut 
2‐3 weeks after final immunization.19 As adjuvants are effective in 
inducing long‐term changes in the immune response, we hypothe‐
sized that these NE‐based vaccines might stably modulate the aller‐
gen‐specific immune response resulting in durable SU. In this study, 
we test the ability of an intranasal NE‐based vaccine to induce long‐
term modulation of established Th2 immunity and SU from allergic 
reactions in a mouse model of cow's milk allergy.
2  | MATERIAL S AND METHODS
2.1 | Antigen and adjuvants
Nanoemulsion adjuvant (NE) was produced by a high‐speed emul‐
sification of ultra‐pure soybean oil with cetylpyridinium chloride, 
G R A P H I C A L  A B S T R A C T
This study evaluates the ability of an intranasal nanoemulsion‐based vaccine to induce long‐term modulation of allergic reactions in a mouse 
model of cow's milk allergy. Intranasal immunization with nanoemulsion adjuvant suppresses Th2 responses and anaphylaxis. The sustained 
unresponsiveness of at least 16 weeks after vaccination suggests that the nanoemulsion vaccine alters the allergic phenotype.
874  |     O'KONEK Et al.
Tween 80 and ethanol in water, with resultant NE droplets with av‐
erage 350‐400 nm diameter.20,21 Aluminum hydroxide (alum, alhy‐
drogel) was purchased from InvivoGen. Casein purified from bovine 
milk, containing the four main types of casein found in cow's milk: α‐
s1 Casein, α‐s2 Casein, β‐Casein, and κ‐Casein, was purchased from 
Sigma and was solubilized in phosphate buffer saline (PBS) and steri‐
lized by sequential filtration through 0.4‐ and 0.2‐µm syringe filters. 
Endotoxin content of all vaccine components was determined by a 
limulus amebocyte lysate (LAL) assay (Pierce). There was no detect‐
able endotoxin in PBS, NE, or alum (Figure S1). The stock solution of 
casein was approximately 5 endotoxin units (EU) per mL; however 
after dilution into the final vaccine formulation, the total amount of 
endotoxin given intranasally to each mouse is 0.004 EU per dose. As 
0.004 EU is equivalent to approximately 0.4 pg of LPS, this amount 
of endotoxin is not anticipated to have major effects.
2.2 | Mice and immunizations
Specific pathogen‐free BALB/c mice (females 3 weeks old) were 
purchased from Jackson Laboratory. Mice were 4 weeks of age at 
the onset of the experiment. The experimental design is shown in 
Figure 1. Allergic sensitization was induced with intraperitoneal 
immunizations (i.p.) of 125 µg bovine casein (Sigma) adsorbed 
on 1 mg alum at weeks 0 and 2. Intranasal (i.n.) immunizations 
were administered as 12 µL (6 µL/nare) of a formulation contain‐
ing 20 µg of casein mixed with 20% NE. Casein mixed with PBS 
alone served as a control. Systemic anaphylaxis was induced by 
i.p. injection of 100 µg casein, and reactions were assessed as de‐
scribed below. For oral challenge experiments, mice were fasted 
for 5‐6 hours to ensure gastric emptying and then were challenged 
with 0.2 mL of 4% fat cow's milk by oral gavage. Mice were chal‐
lenged orally every other day for a total of 7 gavages.22 All ani‐
mal procedures were performed according to the University of 
Michigan Institutional Animal Care and Use Committee and the 
National Institutes of Health guide for the care and use of labora‐
tory animals.
2.3 | Assessment of hypersensitivity reactions
Anaphylactic symptoms were evaluated for 1 hour following chal‐
lenge using the following scoring system (modified from23,24): 0, no 
symptoms; 1, prolonged rubbing and scratching around the nose, 
eyes, or head; 2, puffiness around the eyes or mouth, diarrhea, pilo‐
erection, and/or decreased activity with increased respiratory rate; 
3, labored respiration, wheezing, stridor, and/or cyanosis around 
the mouth and tail; 4, tremor, convulsion, no activity after prodding 
and/or moribund; and 5, death. Rectal temperature was monitored 
for 60 minutes following challenge. Mice were bled 60 minutes 
F I G U R E  1   Protection conferred by 
NE immunization is sustained for at least 
16 wk. (A) Mice were sensitized with 
casein‐alum (CS‐alum) and immunized 
i.n. with 4 administrations of casein‐NE 
(CS‐NE) or casein‐PBS (CS‐PBS). Mice 
were challenged intraperitoneally with 
casein at (B) week 24, 4 wk after the final 
i.n. immunization, or (C) week 36, 16 wk 
after the final i.n. immunization. In order 
to assess sustained unresponsiveness 
(SU), the degree of allergic reactions 
was measured by change in core body 
temperature, clinical anaphylaxis score, 
and serum MCPT‐1 levels as determined 
by ELISA. Statistically significant 
differences (P < .05) are indicated by *
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following challenge, and serum mouse mast cell protease‐1 (MCPT‐1) 
was determined by ELISA (eBioscience).
2.4 | Measurement of serum antibodies
Sera were obtained by saphenous vein bleeding or by cardiac puncture 
posteuthanasia. Serum was separated from whole blood by centrifuga‐
tion at 1500 × g for 5 minutes after allowing coagulation for 30‐60 min‐
utes at room temperature. Serum samples were stored at −20°C until 
analyzed. Casein‐ and cow's milk‐specific IgE antibodies were deter‐
mined by ELISA as described previously.19 Briefly, serially diluted serum 
samples were incubated on microtiter plates coated with 20 µg/mL 
bovine casein or cow's milk. IgE, IgG1, and IgG2a were detected with 
alkaline phosphatase conjugated anti‐mouse IgE (Rockland) and IgG1 
and IgG2a (Jackson ImmunoResearch) antibodies and Sigma Fast™ p‐
nitrophenyl phosphate substrate (Sigma) and quantified by measuring 
the optical density (OD) at 405 nm. The antibody concentrations are 
presented as endpoint titers defined as the reciprocal of the highest 
serum dilution producing an OD above background of naïve sera. The 
cutoff value is determined as the OD (mean + 2 standard deviations) of 
the corresponding dilution of naive sera.25,26
2.5 | Analysis of cytokine production
The cellular recall response was evaluated in lymphocytes isolated 
from mesenteric lymph nodes. Single cell lymphocyte suspensions 
were cultured ex vivo ± casein (25 µg/mL) at 37°C. After 72 hours, 
cytokine secretion was measured in cell culture supernatants using 
Luminex multiplex detection system (Millipore).
2.6 | Acute allergic skin response
The acute allergic skin response (ear swelling at 1 hour) was deter‐
mined in anesthetized mice after intradermal (i.d.) injection of 10 μg 
casein in the ear pinnae. Ear thickness was measured in duplicate 
using a digital micrometer. The allergen‐specific change in ear swell‐
ing was compared with the nonspecific ear swelling due to allergen 
injection in the PBS (sham)‐sensitized group.
2.7 | Mast cell quantification
Eighteen hours after challenge, the duodenum and jejunum were 
fixed in 10% formalin, embedded in paraffin, and cut into 5‐µm thick 
sections. Tissue sections were stained for chloroacetate esterase 
(CAE) activity as previously described.22,27 Quantification of mast 
cells was performed by counting the number of CAE‐positive cells 
from at least 25 fields of view at 40× magnification, and the data are 
reported as number of cells per field.
2.8 | Serum transfer experiments
Mice were sensitized i.p. with casein and alum at weeks 0 and 2 
and immunized i.n. with casein‐NE or casein‐PBS at weeks 6, 12, 
18, and 20 as described above and in Figure 1. At week 24, mice 
were killed and serum was harvested. Serum from mice receiving 
the same treatments was pooled and transferred into naïve recipi‐
ent mice (200 µL/mouse) by injection into the tail vein. Twenty‐four 
hours after serum transfer, recipient mice were challenged orally 
with cow's milk to assess reactivity.
2.9 | Statistics
Statistical comparisons were assessed by the Mann‐Whitney 
test using GraphPad Prism version 7 (GraphPad Software). The P 
value < .05 was considered as significant. Results presented here are 
the representatives of at least two independent experiments.
3  | RESULTS
3.1 | Intranasal immunization with NE adjuvant 
suppresses allergic reactions and anaphylaxis
BALB/c mice were sensitized to the cow's milk protein casein at 
weeks 0 and 2 by i.p. injections of bovine casein adsorbed on alum.19 
Six weeks after sensitization, one group of mice received four, 
monthly i.n. immunizations with casein formulated in NE while the 
others received i.n. casein or PBS as controls. The mice were subse‐
quently challenged intraperitoneally with casein to assess protec‐
tion. At week 24, 4 weeks after the last i.n. immunization, sensitized 
control mice had profound reactions to challenge, indicated by core 
body temperature loss of >5°C and severe symptoms of anaphylac‐
tic shock including pruritus, puffiness around the eyes and mouth, 
labored respiration or wheezing and lack of activity when prodded 
(Figure 1B). As compared to controls, the NE vaccine markedly sup‐
pressed physiological responses to allergen challenge. There was sig‐
nificant improvement in body temperature loss (P = .003) as well as 
anaphylaxis symptom score (P = .002), and mice that received the NE 
vaccine exhibited only mild symptoms of allergic reaction, as none 
experienced respiratory problems or shock. In order to quantify 
mast cell degranulation, MCPT‐1 was measured in serum following 
challenge. Consistent with the clinical symptoms of allergic reaction, 
immunized mice had a significant reduction in MCPT‐1, with average 
levels of 74 ng/mL compared with 528 and 840 ng/mL in control 
groups that received i.n. casein or PBS (P = .0079). No significant dif‐
ferences in reactivity were observed in sensitized mice that received 
i.n. casein in PBS compared to sensitized mice that were not treated 
intranasally with allergen, demonstrating that the four i.n. exposures 
to 20 µg casein did not significantly modulate reactivity. Similarly, 
i.n. administration of NE without allergen had no effect on the sup‐
pression of allergic reactivity (Figure S2).
In order to investigate durability of protection, mice were chal‐
lenged 16 weeks after the final i.n. immunization. The increased time 
between sensitization and challenge did not influence the severity 
of allergic reactions for control mice (Figure 1C). In contrast, im‐
munized mice were protected from challenge as body temperature 
loss, anaphylaxis symptom score, and MCPT‐1 were significantly 
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improved (P = .0001, .0002, and .002, respectively). The protection 
from challenge appeared complete, as there were no differences in 
reactions in NE‐immunized mice compared with nonsensitized mice. 
This indicated that therapeutic immunization with NE results in com‐
plete protection 16 weeks after the final intranasal administration, 
with the protection appearing more pronounced than at earlier time 
points.
3.2 | Intranasal immunization with NE adjuvant 
suppresses allergy‐associated Th2 responses
We have previously reported that allergen‐NE immunization modu‐
lates allergen‐specific Th2‐polarized immunity while inducing IL‐10, 
Th1, and Th17 immune responses.18,19 To confirm this in the milk 
allergy model, mesenteric lymph node cells were stimulated ex vivo 
with casein to characterize the recall response to allergen after 
the 4‐week SU challenge at week 24 (Figure 2A). Upon stimulation 
with casein, cells from casein‐alum‐sensitized mice produced pre‐
dominantly Th2‐type cytokines (IL‐4, IL‐5, IL‐13) with lower levels 
of IFN‐γ, IL‐10, IL‐17, and IL‐22 (Figure 2A). Lymphocytes from mice 
that received subsequent casein‐NE immunizations produced sig‐
nificantly more Th1 cytokines and significantly less Th2 cytokines. 
Casein‐NE significantly increased IL‐10 (P = .01) and the Th17 cy‐
tokines IL‐17 and IL‐22 (P = .0079) and decreased IL‐4 and IL‐13 
(P = .016 and .032, respectively). Consistent with reactivity data 
described above, i.n. administration of casein did not have any sig‐
nificant effects on cytokine production, compared with sensitized 
mice that were not treated i.n. with casein. Lymphocytes from PBS 
control mice (nonsensitized but challenged) did not produce measur‐
able cytokine upon restimulation with casein.
Cytokine production was also characterized after the 16‐week 
SU challenge (week 36) to determine whether modulation of the al‐
lergen‐specific cytokine response persisted for 16 weeks after the 
final i.n. immunization. Consistent with the strong protection from 
F I G U R E  2   Nanoemulsion 
immunization suppresses Th2 immunity 
and induces Th1/Th17 in mice sensitized 
to cow's milk protein. Cellular recall 
immune responses to bovine casein 
were measured in mLN lymphocytes 
harvested from mice at weeks (A) 
24 and (B) 36. Cytokine secretion in 
culture supernatant was determined 
by a Luminex multiplex assay. Cytokine 
production has been normalized to control 
unstimulated lymphocyte cultures for 
each sample. Values are calculated as 
[stimulated] − [unstimulated] = Total (pg/
mL) for each cytokine. Data are expressed 
as mean ± standard deviation. Statistically 
significant differences (P < .05) are 
indicated by *
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challenge at this time point, IL‐4 and IL‐13 production remained sig‐
nificantly suppressed (P = .001 and .007) (Figure 2B). Interestingly, 
from weeks 24 to 30, there was an approximately 3.5‐fold reduction 
in IL‐4 and IL‐13 in the casein‐NE‐immunized animals, while the pro‐
duction of these cytokines was increased in the nonimmunized mice 
possibly as a result of reactivity upon challenge.
Nanoemulsion immunization‐induced enhancement of IFN‐γ, 
IL‐17, and IL‐22 was maintained at week 36 (P = .042, .01 and .0007). 
However, at this later time point, there was no significant difference 
in IL‐10 production between mice that received i.n. instillations of 
casein‐NE or casein‐PBS. While IL‐10 production remained con‐
stant at approximately 4000 ng/mL in mice that received casein‐NE, 
there was a fivefold increase in IL‐10 production in mice receiving 
casein‐PBS. For all cytokines tested, there was largely no detectable 
antigen‐specific cytokine production in the nonsensitized control 
group at week 24, and all cytokines increased at week 36 to low, 
but detectable, levels. This suggests minimal effect from the prior 
casein challenge on casein‐specific cytokine production at week 36 
in nonsensitized animals. Overall, these data demonstrate that the 
modulation of Th2 cytokine production not only remains modulated 
for at least 16 weeks after the final immunization but also becomes 
stronger in the months after immunization.
3.3 | NE reduces mast cell infiltration into tissue and 
protects despite the presence of allergen‐specific IgE 
in the serum
Allergen‐specific antibodies were quantified from the serum 
throughout the course of the study (Figure 3). Sensitization and 
immunization with casein induced similar levels of antibodies spe‐
cific for casein and cow's milk, demonstrating that these antibodies 
bind to casein epitopes that are present in cow's milk. Immunization 
with casein‐NE largely prevented further increases in allergen‐spe‐
cific IgE that occurred in nonimmunized mice. Surprisingly, at week 
24 despite being protected from challenge, serum casein‐ and 
cow's milk‐specific IgE titers were not significantly different in ca‐
sein‐NE‐ and casein‐PBS‐immunized mice (Figure 3A). At week 36, 
allergen‐specific IgE was significantly decreased in the serum of NE‐
immunized mice (P = .007); however, IgE antibody titers remained 
significantly elevated at titers where nonimmunized mice would be 
expected to react to challenge (Figure 3A). While allergen‐specific 
IgG1 titers were not significantly affected by the casein‐NE treat‐
ment (Figure 3B), IgG2a titers were increased more than 20‐fold in 
the serum of mice that received casein‐NE (P < .0001), demonstrat‐
ing a shift in the profile of cow's milk‐specific antibodies (Figure 3C).
To confirm that the NE vaccine could protect from IgE‐mediated 
allergic reactions, the acute allergic skin response to intradermal 
injection of casein was measured. NE treatment reduced the acute 
allergic skin responses compared to the casein‐sensitized control 
mice (Figure 4B). As this further suggested that the NE‐immunized 
mice were protected from IgE‐mediated allergic reactions, we tested 
the ability of NE to protect from reactivity in an additional exper‐
imental food allergy model in which intestinal mast cells drive the 
clinical phenotype.22,28,29 As illustrated in Figure 4A, 2 weeks after 
the final i.n. immunization, mice were challenged orally with cow's 
milk every other day for 2 weeks. NE‐immunized mice were sig‐
nificantly protected from allergic reaction to oral cow's milk chal‐
lenge, as indicated by a >10‐fold reduction in MCPT‐1 (P = .0002) 
(Figure 4C). Mast cells were quantified in the small intestine to de‐
termine whether NE immunization protected through blocking the 
accumulation of mast cells in the tissues. There was an almost 10‐
fold increase in small intestine mast cells in sensitized mice; however, 
mast cell infiltration was significantly lower in NE‐immunized mice 
(P < .0001) and was identical to mast cell numbers observed in non‐
sensitized mice (Figure 4D and Figure S3). These data suggest that 
while allergen‐specific IgE circulates in the blood, the NE‐immunized 
mice are protected from challenge due to the lack of mast cell accu‐
mulation in the tissue.
In order to further assess the role of the humoral immune re‐
sponse in the protection conferred by NE immunization, a passive 
F I G U R E  3   Nanoemulsion immunization modulates allergen‐specific IgE and IgG in serum. Serum casein‐ and cow's milk‐specific (A) 
IgE, (B) IgG1, and (C) IgG2a were measured by ELISA throughout the course of the therapeutic protocol. Statistically significant differences 
(P < .05) are indicated by *
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sensitization experiment was performed. Serum was harvested from 
mice following sensitization and immunization and transferred into 
naïve recipient mice. Recipient mice were challenged to determine 
whether the serum from NE‐immunized mice would confer re‐
activity. Mice that received serum from sensitized mice that were 
immunized with casein‐PBS reacted to challenge, as demonstrated 
by a decrease in core body temperature and increase in MCPT‐1 
(Figure 5). Mice that received serum from casein‐NE‐immunized 
mice had significantly reduced reactions. These data demonstrate 
that while serum in these mice contains allergen‐specific IgE, it does 
not confer sensitively to the allergen.
4  | DISCUSSION
To date, no immune approach to address food allergies has demon‐
strated long‐term protection from reactivity, identified as SU, which 
is an unmet need for the millions of patients with food allergies. We 
have investigated the use of adjuvants to induce a durable modula‐
tion of allergen‐specific immune responses that is effective with few 
immunizations. Our previous results demonstrated that NE‐based 
allergy vaccines could suppress peanut allergy in several mouse 
models a few weeks after administration of the last immunization. 
The present studies investigate whether the immunomodulation of 
the allergen‐specific response by NE vaccine could induce durable 
immune alterations capable of conferring long‐term SU and protec‐
tion from allergen challenge. We demonstrated that NE‐immunized 
mice were protected for 16 weeks following NE immunization and 
these mice were completely unresponsive to allergen challenge at 
that late time point. Protection from allergen challenge correlated 
with continued suppression of allergen‐specific Th2 immune re‐
sponses, suggesting that the changes in the allergic immune pheno‐
type were also durable.
While allergen‐specific IgE is commonly used to diagnose food 
allergies, many patients with allergen‐specific IgE in the blood do 
not react upon consumption of that food.30,31 In this study, while 
cow's milk‐specific IgE was significantly decreased in the serum of 
NE‐immunized mice at the end of the study, IgE titers remained sig‐
nificantly elevated to similar levels where sensitized control (non‐NE 
vaccinated) mice reacted to challenge. Since these NE‐immunized 
mice were protected from IgE‐mediated allergic reactions, this sug‐
gests that similar to food allergic humans, serum allergen‐specific 
IgE is not completely predictive of clinical reactivity. In addition, 
while serum casein‐specific IgE was not completely suppressed in 
NE‐immunized mice, there was complete suppression of mast cell 
accumulation in the intestine after oral challenge, consistent with 
reports that food allergic reactions in murine models of food allergy 
are dependent upon tissue mast cell infiltration.22,28
F I G U R E  4   Nanoemulsion immunization protects from mast 
cell–mediated allergic reactions. (A) Mice were sensitized with 
casein‐alum (CS‐alum) and immunized i.n. with 4 administrations of 
casein‐NE (CS‐NE) or casein‐PBS (CS‐PBS). At week 24, mice were 
challenged either (B) intradermally (i.d) with casein or (C) orally with 
cow's milk for a total of 7 challenges over 2 wk. (B) The effect of 
NE immunization on the acute allergic skin response was measured 
before and 1 h after the i.d. challenge with casein. The effect of NE 
immunization on allergic reaction to oral challenged was measured 
by (C) serum MCPT‐1 levels and (D) the number of mast cells in the 
jejunum after the 7th oral cow's milk challenge. Histology images 
were obtained at 40x magnification and cells counted per field of 
vision. Statistically significant differences (P < .05) are indicated 
by *
F I G U R E  5   Serum from NE‐immunized mice does not induce 
passive sensitization in recipient mice. (A) Serum from casein‐
sensitized mice that received i.n. PBS, casein‐PBS or casein‐NE was 
harvested at week 24 and transferred into naïve recipient mice. 
Twenty‐four hours later, recipient mice were challenged orally 
with cow's milk and reactivity was measured by (B) change in body 
temperature and (C) serum MCPT‐1 levels. Statistically significant 
differences (P < .05) are indicated by *
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Serum transfer from NE‐immunized mice was used to dissect the 
humoral and cellular immune mechanisms responsible for the pro‐
tection induced by the NE vaccines. While transfer of serum from 
sensitized and nonimmunized mice passively sensitized mice, serum 
from sensitized and NE‐immunized mice did not result in reactivity 
in recipient mice. The serum from NE‐immunized mice contained al‐
lergen‐specific IgE; however, the transfer of this IgE did not transfer 
reactivity. This suggests that the modulation of the allergen‐specific 
antibody profile may play a key role in the protection from challenge 
observed following NE immunization. Modulation of the humoral 
immune response can lead to protection through multiple mecha‐
nisms. NE immunization may induce blocking antibody that can neu‐
tralize the allergen before it binds to IgE on effector cells.32,33 Mast 
cell degranulation can also be suppressed through the activation of 
the inhibitory Fc receptor FcγRIIb.33‐35 Allergen‐specific IgG2a is 
significantly increased in NE‐immunized mice at both the 24‐ and 
36‐week challenges and may be involved in the inhibition of mast 
cell activation either through the activation of FcγRIIb or by blocking 
allergen from binding to IgE. Together, these data suggest that while 
allergen‐specific IgE circulates in the blood, NE‐immunized mice may 
be protected from clinical reactions due to reduced mast cell recruit‐
ment, accumulation, and activation in the gut. These results also 
suggest that tissue mast cell infiltration would be a strong predictor 
of food allergy reactivity compared to allergen‐specific serum IgE.
Other studies have demonstrated efficacy of immunotherapies 
for food allergies in mice but have typically challenged mice within 
2 weeks of the last therapeutic intervention.36‐45 As this is a time‐
point where the effect of desensitization could not have worn off, 
we modified this approach by evaluating SU in excess of 3 months 
after discontinuation of therapy. While our studies were performed 
in mice, comparisons to studies of OIT performed in both mice and 
humans can provide insights into how this might translate into pro‐
tection in humans. Studies of OIT in mice have demonstrated that 
protection is lost 2 weeks after stopping OIT.46 In humans, however, 
OIT has led to SU intervals of 2‐8 weeks in a fraction of patients. 
Despite this, most OIT human trials also have shown that as time 
posttreatment increases the percentage of patients who pass the 
DBPCFC decreases.47,48 Thus, it is significant that the NE vaccines 
induce protective immunity that persists in all mice for at least 
16 weeks off treatment. It also suggests that the complete unre‐
sponsiveness at 16 weeks after the last immunization in mice could 
translate into a significant duration of protection in humans.
Desensitization and tolerance are two distinct outcomes of im‐
munotherapy, and it is important to distinguish between the two. 
Desensitization is an increase in the threshold amount of food that can 
be ingested without reaction while on the therapy. Desensitization is 
mediated by changes in effector cells, such as mast cells, but does not 
involve modulation of the underlying allergen‐specific immune mech‐
anisms. Thus, desensitization is temporary and the individual remains 
allergic to the allergen, reacting to the antigen soon after the therapy 
is stopped. Conversely, true tolerance is more permanent protection 
from reaction after discontinuation of the immunotherapy. Tolerance 
involves modulation of effector cells as well as allergen‐specific 
immune cells, typically through the induction of regulatory mecha‐
nisms.49,50 While the sustained unresponsiveness observed with OIT 
is likely mostly due to desensitization, the durable protective immunity 
and immunomodulation induced by the NE vaccines presented here 
are not consistent with desensitization and suggest an immune pheno‐
type more consistent with tolerance.
We have previously reported that therapeutic immunization with 
NE induces Tregs.18,19 Increases in both Tregs and IL‐10 suggest that 
the suppression of Th2 immunity and subsequent protection from 
allergen challenge is due to the induction of regulatory mechanisms. 
A similar induction of Tregs and IL‐10, as well as IFN‐ γ, has been 
reported in grass pollen allergic individuals with decreased Th2 im‐
mune responses after allergen immunotherapy.51,52 The induction 
of IL‐10 is not sufficient for the suppression of reactivity, as in this 
study casein‐sensitized mice that received i.n. casein‐PBS retain 
reactivity at week 36 despite having increased IL‐10. This suggests 
that the induction of IL‐10 without the suppression of Th2 immune 
responses is not sufficient to suppress reactivity.
In summary, administering allergen with NE induces long‐term 
immune changes that provide protection from allergen challenge 
for months after discontinuation of therapy. The cytokine profiles in 
allergic mice after immunization with the NE vaccines showed Th2 
cytokines remained significantly suppressed and Th1/Th17 allergen‐
specific responses were augmented. This suggests allergen/NE immu‐
nization reprograms the immune system toward a balanced immune 
response that may have more lasting effects in suppressing allergic 
disease than traditional allergen desensitization immunotherapy.
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